← Cancer trial database
Trial
Non-small cell lung cancer

Phase 2 pumitamig PD‑L1×VEGF‑A bispecific antibody neoadjuvant platform in resectable NSCLC.

Trial status

Registered, Not Yet Recruiting

Status as of

Got an update?
Trial ID
NCT07871214 on ClinicalTrials.gov
Cancer type
Non-Small Cell Lung Cancer (NSCLC)
Stage of research
Exploratory
Location
Global: US, Canada, Australia, China, Taiwan, South Korea, Japan, UK, and Europe
Published in
New in Oncology - Nov 12, 2026

ROSETTA Lung-220 is a Phase 2, randomized, open-label, multicenter, multi‑arm neoadjuvant platform study testing pumitamig-based regimens given before surgery to assess safety, tolerability, and whether patients can still proceed to planned resection on time. Pumitamig (also known as BNT327/BMS‑986545/PM8002) is a PD‑L1 and VEGF‑A–directed bispecific antibody designed to pair immune checkpoint blockade with anti‑angiogenic signaling inhibition in one molecule, and here it is combined with standard platinum doublet chemotherapy (e.g., cisplatin or carboplatin with pemetrexed or paclitaxel, depending on histology). The sponsor is Bristol Myers Squibb, with BioNTech listed as collaborator, positioning this as an important “partnered” immuno-oncology asset being pushed across multiple ROSETTA programs. Eligible participants are treatment‑naive patients with resectable stage IIA–IIIB NSCLC and evaluable PD‑L1 expression, a group where current care increasingly uses perioperative chemo‑immunotherapy (commonly nivolumab or pembrolizumab with platinum chemotherapy) followed by surgery and risk-adapted adjuvant therapy; this study asks whether adding VEGF‑A targeting via a bispecific can deepen pathologic responses without compromising surgical feasibility. The commercial/scientific angle is leveraging a single bispecific to deliver dual PD‑(L)1 + VEGF biology that previously required multi-drug combinations (e.g., checkpoint inhibitor plus bevacizumab), potentially simplifying development and differentiation if perioperative endpoints look strong.

More in non-small cell lung cancer

See all entries in non-small cell lung cancer →